| Literature DB >> 15552778 |
Timothy C Kennedy1, Fred R Hirsch.
Abstract
Recent exciting advances have been made in identifying potential molecular markers in sputum which may soon be ready for validation trials to indicate high risk for lung cancer, especially central airway squamous cell lung cancer. Hopefully, a set of biomarkers will be identified with higher sensitivity, specificity, and enough lead-time compared to traditional cytopathology to justify endobronchial evaluation and local therapy to help reduce lung-cancer mortality in high-risk patients.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15552778 DOI： 10.1016/j.lungcan.2004.07.996
Source DB: PubMed Journal: Lung Cancer ISSN： 0169-5002 Impact factor: 5.705